219 related articles for article (PubMed ID: 33744388)
1. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
2. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Kang YW; Lee JE; Jung KH; Son MK; Shin SM; Kim SJ; Fang Z; Yan HH; Park JH; Han B; Cheon MJ; Woo MG; Lim JH; Kim YS; Hong SS
Cancer Lett; 2018 Dec; 438():174-186. PubMed ID: 30217561
[TBL] [Abstract][Full Text] [Related]
3. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
4. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine.
Wei R; Penso NEC; Hackman RM; Wang Y; Mackenzie GG
Nutrients; 2019 Aug; 11(8):. PubMed ID: 31405071
[TBL] [Abstract][Full Text] [Related]
6. Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.
Paik WH; Ryu JK; Jeong KS; Park JM; Song BJ; Lee SH; Kim YT; Yoon YB
World J Gastroenterol; 2014 Jul; 20(26):8545-57. PubMed ID: 25024609
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Shimizu K; Nishiyama T; Hori Y
Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
9. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
[TBL] [Abstract][Full Text] [Related]
11. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
12. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.
Yeo D; Huynh N; Beutler JA; Christophi C; Shulkes A; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2014 May; 346(2):264-72. PubMed ID: 24491405
[TBL] [Abstract][Full Text] [Related]
13. DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell.
Guo Q; Qin W
J Cell Mol Med; 2015 Dec; 19(12):2832-41. PubMed ID: 26395974
[TBL] [Abstract][Full Text] [Related]
14. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
Treviño JG; Verma M; Singh S; Pillai S; Zhang D; Pernazza D; Sebti SM; Lawrence NJ; Centeno BA; Chellappan SP
Mol Cancer Ther; 2013 Dec; 12(12):2722-34. PubMed ID: 24107447
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
16. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
[TBL] [Abstract][Full Text] [Related]
17. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
[TBL] [Abstract][Full Text] [Related]
18. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Duan W; Chen K; Jiang Z; Chen X; Sun L; Li J; Lei J; Xu Q; Ma J; Li X; Han L; Wang Z; Wu Z; Wang F; Wu E; Ma Q; Ma Z
Cancer Lett; 2017 Jan; 385():225-233. PubMed ID: 27773749
[TBL] [Abstract][Full Text] [Related]
19. Engineering of an EpCAM-targeting cyclic peptide to improve the EpCAM-mediated cellular internalization and tumor accumulation of a peptide-fused antibody.
Park SW; Jun SY; Kim JS; Kim YS
Biochem Biophys Res Commun; 2021 Oct; 573():35-41. PubMed ID: 34388452
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
